AU2017211976B2 - Means and methods for staging, typing and treating a cancerous disease - Google Patents

Means and methods for staging, typing and treating a cancerous disease Download PDF

Info

Publication number
AU2017211976B2
AU2017211976B2 AU2017211976A AU2017211976A AU2017211976B2 AU 2017211976 B2 AU2017211976 B2 AU 2017211976B2 AU 2017211976 A AU2017211976 A AU 2017211976A AU 2017211976 A AU2017211976 A AU 2017211976A AU 2017211976 B2 AU2017211976 B2 AU 2017211976B2
Authority
AU
Australia
Prior art keywords
cells
cancer
dcc
dccs
somatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017211976A
Other languages
English (en)
Other versions
AU2017211976A1 (en
Inventor
Isabelle HODAK
Martin Hoffmann
Christoph Klein
Sebastian SCHEITLER
Melanie WERNER-KLEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Regensburg
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung eV
Original Assignee
University of Regensburg
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Regensburg, Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung eV filed Critical University of Regensburg
Publication of AU2017211976A1 publication Critical patent/AU2017211976A1/en
Application granted granted Critical
Publication of AU2017211976B2 publication Critical patent/AU2017211976B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2017211976A 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease Active AU2017211976B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
EP16152883.1 2016-01-27
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (2)

Publication Number Publication Date
AU2017211976A1 AU2017211976A1 (en) 2018-08-02
AU2017211976B2 true AU2017211976B2 (en) 2022-09-22

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017211976A Active AU2017211976B2 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Country Status (9)

Country Link
US (1) US11702701B2 (cg-RX-API-DMAC10.html)
EP (2) EP3199641B1 (cg-RX-API-DMAC10.html)
JP (1) JP2019508032A (cg-RX-API-DMAC10.html)
CN (1) CN108770360B (cg-RX-API-DMAC10.html)
AU (1) AU2017211976B2 (cg-RX-API-DMAC10.html)
CA (1) CA3012404A1 (cg-RX-API-DMAC10.html)
ES (1) ES2905208T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201805990XA (cg-RX-API-DMAC10.html)
WO (1) WO2017129753A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1109938T3 (da) 1998-09-18 2002-05-27 Micromet Ag DNA-amplificering af en enkelt celle
AU2002216009A1 (en) * 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
ITRM20110149A1 (it) * 2011-03-25 2012-09-26 Massimo Zollo Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione.
WO2013009632A2 (en) * 2011-07-08 2013-01-17 The University Of Utah Research Foundation Methods of detecting hereditary cancer predisposition
JP2015500035A (ja) * 2011-12-10 2015-01-05 アボツト・モレキユラー・インコーポレイテツド 悪性黒色腫の診断および悪性黒色腫の転移の予後予測のための物質および方法
EP3033150A4 (en) * 2013-08-13 2017-06-28 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
WO2015118077A1 (en) 2014-02-05 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Error-free sequencing of dna

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARBST, K. et al., "Molecular and genetic diversity in the metastatic process of melanoma", 2014. J Pathol, Vol.233, No.1, pg. 39-50 *
PICARD, M. et al., "Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection", 2014. Br. J. Dermatol., Vol. 171, No. 1, pg. 108-114 *
SANBORN, J. Z. et al., "Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination", 2015. PNAS, Vol. 112, No. 35, pgs. 10995-11000. *
TRINH, V.A. & HWU, W.J., "Chemoprevention for Brain Metastases", 2011. Curr. Oncol. Rep., Vol.14, No.1, pg. 63-69 *
ULMER, A. et al., "Quantitative measurement of melanoma spread in sentinel lymph nodes and survival", 2014. PLOS Med, Vol. 11, No. 2, pg.1-17 *

Also Published As

Publication number Publication date
CA3012404A1 (en) 2017-08-03
ES2905208T3 (es) 2022-04-07
AU2017211976A1 (en) 2018-08-02
EP3199641A1 (en) 2017-08-02
EP3408411A1 (en) 2018-12-05
JP2019508032A (ja) 2019-03-28
US11702701B2 (en) 2023-07-18
SG11201805990XA (en) 2018-08-30
US20190062845A1 (en) 2019-02-28
KR20180102674A (ko) 2018-09-17
EP3199641B1 (en) 2021-09-29
WO2017129753A8 (en) 2017-10-19
WO2017129753A1 (en) 2017-08-03
CN108770360B (zh) 2022-06-14
CN108770360A (zh) 2018-11-06

Similar Documents

Publication Publication Date Title
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
TW201632629A (zh) 用於癌症診斷與預後的方法
CN109476698B (zh) 基于基因的炎性肠病诊断
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
KR20090127939A (ko) 유방암의 위험도 평가, 진단, 예후 및 치료용 마커인 염색체 ２ 및 염색체 １６ 상의 유전적 변이
KR20180049093A (ko) 신규한 바이오마커 및 암의 치료 방법
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
CN111405901A (zh) 含有miRNA的癌症治疗用医药组合物
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
CN108624683B (zh) Usp48基因突变在acth型垂体腺瘤分子诊断中的应用
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
KR102647919B1 (ko) App 돌연변이 세포 및 이의 이용
CN108770360B (zh) 对癌性疾病进行分期、分型和治疗的手段和方法
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
CN113718033A (zh) 生物标记物在制备用于预测结直肠癌患者预后的试剂中的应用
CN116356008A (zh) 先天性心脏病相关setd2基因新发变异位点及其应用
US20040138441A1 (en) Novel gene functionally related to dyslexia
US20090258344A1 (en) Methods for identifying risk of breast cancer and treatments thereof
KR20050008644A (ko) 위암에서의 유전자 발현 프로파일
US20030219787A1 (en) Novel human gene functionally related to dyslexia
HK40102639A (en) Methods of loading extracellular vesicles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)